Microbiota in Inflammatory Bowel Disease Pathogenesis and Therapy: Is It All About Diet?
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Inflammatory bowel disease (IBD), including ulcerative colitis, Crohn's disease, and unclassified IBD, continues to cause significant morbidity. While its incidence is increasing, no clear etiology and no cure have yet been discovered. Recent findings suggest that IBD may have a multifactorial etiology, where complex interactions between genetics, epigenetics, environmental factors (including diet but also infections, antibiotics, and sanitation), and host immune system lead to abnormal immune responses and chronic inflammation. Over the past years, the role of altered gut microbiota (in both composition and function) in IBD pathogenesis has emerged as an outstanding area of interest. According to new findings, gut dysbiosis may appear as a key element in initiation of inflammation in IBD and its complications. Moreover, complex metagenomic studies provide possibilities to distinguish between IBD types and appreciate severity and prognosis of the disease, as well as response to therapy. This review provides an updated knowledge of recent findings linking altered bacterial composition and functions, viruses, and fungi to IBD pathogenesis. It also highlights the complex genetic, epigenetic, immune, and microbial interactions in relation to environmental factors (including diet). We overview the actual options to manipulate the altered microbiota, such as modified diet, probiotics, prebiotics, synbiotics, antibiotics, and fecal transplantation. Future possible therapies are also included. Targeting altered microbiota could be the next therapeutic personalized approach, but more research and well‐designed comparative prospective studies are required to formulate adequate directions for prevention and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S. J., Yassour, M., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.005 · Cited by 3,220
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota
Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., et al. (2013) · Nature · doi:10.1038/nature12331 · Cited by 2,872 · cited 1×
“Butyrate activates regulatory T cells also by affecting epigenetic control of the Foxp3 promoter.(70) Therefore, low levels of butyrate (induced by diet in conjunction with microbiota) could be involved in initiation/perpetuation of inflammation in IBD.”
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
Morgan, X. C., Tickle, T. L., Sokol, H., Gevers, D., Devaney, K. L., Ward, D. V., Reyes, J. A., Shah, S. A., LeLeiko, N., Snapper, S. B., et al. (2012) · Genome Biology · doi:10.1186/gb-2012-13-9-r79 · Cited by 2,713
A framework for human microbiome research
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11209 · Cited by 2,650
Singh, N., Gurav, A., Sivaprakasam, S., Brady, E., Padia, R., Shi, H., Thangaraju, M., Prasad, P. D., Manicassamy, S., Munn, D. H., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.12.007 · Cited by 2,368 · cited 2×
“It upregulates IL-10, reduces expression of TNFα–related cytokines, and inhibits IL-12, possibly by inhibiting the activity of NF-κB and STAT-3 expression.(69,128,129) Butyrate activates regulatory T cells also by affecting epigenetic control of the Foxp3 promoter.”
Round, J. L., & Mazmanian, S. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909122107 · Cited by 2,233
Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome
Chassaing, B., Koren, O., Goodrich, J. K., Poole, A. C., Srinivasan, S., Ley, R. E., & Gewirtz, A. T. (2015) · Nature · doi:10.1038/nature14232 · Cited by 2,055 · cited 1×
“Emulsifiers, such as polysorbate 80 (used in ice creams, whipping creams, dessert toppings, condiments, and dill pickles) and carboxymethylcellulose (E 466, used in dairy products, processed meats, and breads), have deleterious effects on microbiota and could promote IBD, as shown in mice.(133) In vitro studies showed…”
Machiels, K., Joossens, M., Sabino, J., De Preter, V., Arijs, I., Eeckhaut, V., Ballet, V., Claes, K., Van Immerseel, F., Verbeke, K., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-304833 · Cited by 1,904
The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
Kostic, A. D., Xavier, R. J., & Gevers, D. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.009 · Cited by 1,789
Darfeuille-Michaud, A., Boudeau, J., Bulois, P., Neut, C., Glasser, A.-L., Barnich, N., Bringer, M.-A., Swidsinski, A., Beaugerie, L., & Colombel, J.-F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.061 · Cited by 1,566 · cited 2×
“Scientific evidence linking gut microbiota to inflammatory bowel disease (IBD).(11,17,21,23,27,42,62,77,88,110,120,124,155,212-213,218-219) AIEC, adherent-invasive Escherichia coli; CD, Crohn’s disease; UC, ulcerative colitis; VSL#3, mixture of 4 strains of Lactobacillus (acidophilus, bulgaricus, casei, plantarum), 3…”
Moayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.001 · Cited by 1,499 · cited 1×
“The extended version of this RCT included more patients and showed almost the same significant results: remission in 24% (of 35 patients receiving FMT) vs 5% (of 35 patients on placebo).(202) Contrary to these results, the RCT by Rossen et al(203) showed no significant difference in clinical and endoscopic remission b…”
Sellon, R. K., Tonkonogy, S., Schultz, M., Dieleman, L. A., Grenther, W., Balish, E., Rennick, D. M., & Sartor, R. B. (1998) · Infection and Immunity · doi:10.1128/iai.66.11.5224-5231.1998 · Cited by 1,483
Disease-Specific Alterations in the Enteric Virome in Inflammatory Bowel Disease
Norman, J. M., Handley, S. A., Baldridge, M. T., Droit, L., Liu, C. Y., Keller, B. C., Kambal, A., Monaco, C. L., Zhao, G., Fleshner, P., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.002 · Cited by 1,285 · cited 1×
“Scientific evidence linking gut microbiota to inflammatory bowel disease (IBD).(11,17,21,23,27,42,62,77,88,110,120,124,155,212-213,218-219) AIEC, adherent-invasive Escherichia coli; CD, Crohn’s disease; UC, ulcerative colitis; VSL#3, mixture of 4 strains of Lactobacillus (acidophilus, bulgaricus, casei, plantarum), 3…”
Low counts of Faecalibacterium prausnitzii in colitis microbiota
Sokol, H., Seksik, P., Furet, J. P., Firmesse, O., Nion-Larmurier, I., Beaugerie, L., Cosnes, J., Corthier, G., Marteau, P., & Doré, J. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20903 · Cited by 1,275 · cited 16×
“The unaffected relatives had fecal microbiota characterized by lower levels of Collinsella aerofaciens and a member of the E coli– Shigella group and a higher level of Ruminococcus torques than HCs.65 Hedin et al described very recently a mucosal dysbiosis in healthy siblings of patients with CD. Healthy relatives had…”
InfluentialConsensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease
Ruemmele, F. M., Veres, G., Kolho, K. L., Griffiths, A., Levine, A., Escher, J. C., Amil Dias, J., Barabino, A., Braegger, C. P., Bronsky, J., et al. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.04.005 · Cited by 1,083 · cited 2×
“EEN is recommended as first-line therapy to induce remission in children with active luminal CD, over 6–8 weeks, having a safety profile.(41,144) EEN is not useful in UC.”
Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives
Joossens, M., Huys, G., Cnockaert, M., De Preter, V., Verbeke, K., Rutgeerts, P., Vandamme, P., & Vermeire, S. (2011) · Gut · doi:10.1136/gut.2010.223263 · Cited by 1,063 · cited 16×
“The unaffected relatives had fecal microbiota characterized by lower levels of Collinsella aerofaciens and a member of the E coli– Shigella group and a higher level of Ruminococcus torques than HCs.65 Hedin et al described very recently a mucosal dysbiosis in healthy siblings of patients with CD. Healthy relatives had…”
InfluentialRossen, N. G., Fuentes, S., van der Spek, M. J., Tijssen, J. G., Hartman, J. H. A., Duflou, A., Löwenberg, M., van den Brink, G. R., Mathus-Vliegen, E. M. H., de Vos, W. M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.045 · Cited by 921
A Phase I Trial With Transgenic Bacteria Expressing Interleukin-10 in Crohn’s Disease
Braat, H., Rottiers, P., Hommes, D. W., Huyghebaert, N., Remaut, E., Remon, J., van Deventer, S. J. H., Neirynck, S., Peppelenbosch, M. P., & Steidler, L. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.03.028 · Cited by 786 · cited 1×
“Lactococcus lactis genetically engineered to secrete IL-10 was able, in a small open-label trial, to decrease the clinical activity in CD.(208) In UC, fecal concentration of mucus-degrading bacterial enzymes (particularly proteases, sulfatases, and sialidases) correlates with disease activity.”
Furrie, E., Macfarlane, S., Kennedy, A., Cummings, J. H., Walsh, S. V., O’Neil, D. A., & Macfarlane, G. T. (2005) · Gut · doi:10.1136/gut.2004.044834 · Cited by 766 · cited 1×
“B longum + synergy 1 (OF-IN) had, in an RCT, a significant decrease in clinical activity, sigmoidoscopic and histological scores, and proinflammatory cytokine levels (TNF-α and IL-1) vs placebo.(182) B longum + psyllium improved quality of life in a large RCT.”
Brest, P., Lapaquette, P., Souidi, M., Lebrigand, K., Cesaro, A., Vouret-Craviari, V., Mari, B., Barbry, P., Mosnier, J.-F., Hébuterne, X., et al. (2011) · Nature Genetics · doi:10.1038/ng.762 · Cited by 563 · cited 1×
“MiRNA-196 is overexpressed in the inflamed epithelium of patients with CD and may reduce IRGM-mediated autophagy.(39) Also, adherent-invasive Escherichia coli (AIEC) can downregulate autophagy in intestinal epithelial cells of patients with CD by increasing levels of miRNA-30C and miRNA-130A.”
Martinez-Medina, M., Denizot, J., Dreux, N., Robin, F., Billard, E., Bonnet, R., Darfeuille-Michaud, A., & Barnich, N. (2014) · Gut · doi:10.1136/gutjnl-2012-304119 · Cited by 539
Colman, R. J., & Rubin, D. T. (2014) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2014.08.006 · Cited by 475
Lindsay, J. O. (2006) · Gut · doi:10.1136/gut.2005.074971 · Cited by 471 · cited 1×
“In an open-label trial, FOS led to significant decrease in the activity score, as well as a significant increase in the levels of Bifidobacterium and improvement in dendritic cell functions.(178) However, FOS were of no clinical benefit in 2 larger RCTs,(179,180) despite the increase in fecal butyrate and acetaldehyde…”
Willing, B., Halfvarson, J., Dicksved, J., Rosenquist, M., Järnerot, G., Engstrand, L., Tysk, C., & Jansson, J. K. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20783 · Cited by 455
Integrated Metagenomics/Metaproteomics Reveals Human Host-Microbiota Signatures of Crohn's Disease
Erickson, A. R., Cantarel, B. L., Lamendella, R., Darzi, Y., Mongodin, E. F., Pan, C., Shah, M., Halfvarson, J., Tysk, C., Henrissat, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049138 · Cited by 395
Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease
Conte, M. P., Schippa, S., Zamboni, I., Penta, M., Chiarini, F., Seganti, L., Osborn, J., Falconieri, P., Borrelli, O., & Cucchiara, S. (2006) · Gut · doi:10.1136/gut.2005.078824 · Cited by 383
Hold, G. L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i5.1192 · Cited by 365
Shen, J., Zuo, Z.-X., & Mao, A.-P. (2014) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000437495.30052.be · Cited by 364 · cited 4×
“Studies included only adult patients and were extensively described recently.(159,164,165) In prophylaxis of pouchitis, VSL#3 was very efficacious in an RCT, as was Lactobacillus GG (but compared with historical controls).”
InfluentialBenjamin, J. L., Hedin, C. R. H., Koutsoumpas, A., Ng, S. C., McCarthy, N. E., Hart, A. L., Kamm, M. A., Sanderson, J. D., Knight, S. C., Forbes, A., et al. (2011) · Gut · doi:10.1136/gut.2010.232025 · Cited by 361
Benchimol, E. I., Mack, D. R., Guttmann, A., Nguyen, G. C., To, T., Mojaverian, N., Quach, P., & Manuel, D. G. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.52 · Cited by 258 · cited 1×
“Immigrants from areas with a low incidence of IBD who move to areas with a high incidence have an increased risk of IBD,(6,7) which is correlated with a younger age at arrival in high-incidence areas.(7) Altered gut microbiota in IBD has been well documented in many studies from different regions of the world, and it…”
Jonkers, D., Penders, J., Masclee, A., & Pierik, M. (2012) · Drugs · doi:10.2165/11632710-000000000-00000 · Cited by 240
Kump, P. K., Gröchenig, H.-P., Lackner, S., Trajanoski, S., Reicht, G., Hoffmann, K. M., Deutschmann, A., Wenzl, H. H., Petritsch, W., Krejs, G. J., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e31829ea325 · Cited by 235 · cited 1×
“However, early efforts to use FMT for the treatment of IBD have been rather disappointing.(198,199) A 2014 systematic review and meta-analysis included 18 studies in both adults and children.”
Ishikawa, H., Matsumoto, S., Ohashi, Y., Imaoka, A., Setoyama, H., Umesaki, Y., Tanaka, R., & Otani, T. (2011) · Digestion · doi:10.1159/000322977 · Cited by 197 · cited 1×
“B breve + galacto-oligosaccharides showed significant endoscopic improvement, as well as reduced fecal counts of Bacteroidetes vs controls.(184) A small open-label study used inulin + a mixture of PRO (6 strains of Lactobacillus, Bifidobacterium infantis, and S thermophilus) in mild/moderate UC on 5ASA, with clinical…”
Mukhopadhya, I., Thomson, J. M., Hansen, R., Berry, S. H., El-Omar, E. M., & Hold, G. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021490 · Cited by 145
Ohkusa, T., Kato, K., Terao, S., Chiba, T., Mabe, K., Murakami, K., Mizokami, Y., Sugiyama, T., Yanaka, A., Takeuchi, Y., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.84 · Cited by 138
Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study
Suzuki, A., Mitsuyama, K., Koga, H., Tomiyasu, N., Masuda, J., Takaki, K., Tsuruta, O., Toyonaga, A., & Sata, M. (2006) · Nutrition · doi:10.1016/j.nut.2005.04.013 · Cited by 58
Cited by
The Impact of Oxidative Stress in Human Pathology: Focus on Gastrointestinal Disorders
Vona, R., Pallotta, L., Cappelletti, M., Severi, C., & Matarrese, P. (2021) · Antioxidants · doi:10.3390/antiox10020201 · Cited by 431
Thomas, S., Izard, J., Walsh, E., Batich, K., Chongsathidkiet, P., Clarke, G., Sela, D. A., Muller, A. J., Mullin, J. M., Albert, K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2929 · Cited by 367
REV-ERBα integrates colon clock with experimental colitis through regulation of NF-κB/NLRP3 axis
Wang, S., Lin, Y., Yuan, X., Li, F., Guo, L., & Wu, B. (2018) · Nature Communications · doi:10.1038/s41467-018-06568-5 · Cited by 352
Interactions between Intestinal Microbiota and Host Immune Response in Inflammatory Bowel Disease
Zhang, M., Sun, K., Wu, Y., Yang, Y., Tso, P., & Wu, Z. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00942 · Cited by 347
“The effects of probiotics are mediated by modulating the mucosal inflammation system, enhancing competitive exclusion to pathogenic bacteria, regulating the secretion of cytokines involved in the development of IBD, or modulating intestinal permeability (109, 178) (Figure 3).”
BackgroundGanji‐Arjenaki, M., & Rafieian‐Kopaei, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.25911 · Cited by 314
“…as primary cause which leads to inflammatory reactions (Gevers et al., 2014; Haberman et al., 2015; Hold et al., 2014; Morgan et al., 2012; Orel & Kamhi Trop, 2014; Ruemmele, Pigneur, & Garnier-Lengliné, 2014; Sepehri, Kotlowski, Bernstein, & Krause, 2007; Serban, 2015; Walker et al., 2011).”
Metadata
- Authors
- Serban, D. E.
- Venue
- Nutrition in Clinical Practice
- Publisher
- Wiley
- Published
- 2015-10-09
- Volume
- 30
- Issue
- 6
- Pages
- 760-779
- ISSN
- 0884-5336 (ISSN-L)
- 1941-2452
- OpenAlex
- W2217225284
- Cited by
- 75
- References
- 36
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.